CIK 0001582313 · Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980661854
- Phone
- (604) 484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-09 | DiFabio Andrea Chief Legal Officer | Option exercise · Performance Share Units 10b5-1 | −7,500 | 0 | ||
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +75,000 | $8.40 | $630K | 81,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −21,791 | $58.81 | $1.3M | 59,209 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −31,694 | $59.88 | $1.9M | 27,515 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −21,515 | $60.49 | $1.3M | 6,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +25,000 | $3.10 | $78K | 31,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −12,479 | $59.50 | $743K | 18,521 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −10,072 | $60.47 | $609K | 8,449 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −2,449 | $61.26 | $150K | 6,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +105,000 | $4.75 | $499K | 111,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −43,348 | $59.26 | $2.6M | 72,652 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −61,652 | $60.08 | $3.7M | 6,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +65,000 | $9.44 | $614K | 71,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 | −65,000 | $62.06 | $4.0M | 6,000 |
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 | +20,000 | 26,000 | ||
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option 10b5-1 | −75,000 | 0 | ||
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option 10b5-1 | −25,000 | 0 | ||
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option 10b5-1 | −105,000 | 0 | ||
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option 10b5-1 | −65,000 | 0 | ||
| 2026-03-09 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Performance Share Units 10b5-1 | +20,000 | 20,000 |
Page 4 of 16 · 308 trades